Prostate Biopsy

ExactVu OPTIMUM: Optimization of Prostate Biopsy – Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer (EVU-2021-001)

Phase: N/A
Study Product: Optimization of prostate biopsy- ExactVu (no MRI) vs Uronav vs ExactVu fusion with MRI- pts must enroll in study before getting MRI
Estimated Study Completion Date: December 2024 Identifier: NCT05220501

Newly Diagnosed Prostate Cancer

Focal Therapy

Francis Medical Vapor-2: Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR

Phase: N/A
Study Product: Vanquish Water Vapor Ablation locatlized FIR PCa (GG 2 & PSA < 15)
Estimated Study Completion Date: April 2029 Identifier: NCT05683691

Radical Prostatectomy

PROTEUS substudy: A Study of ERLEADA (Apalutamide) in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Phase: 3
Study Product: ADT + Apa- 6M before and after RP vs RP + SOC (1:3) (Gleason ≥8 or PSA ≥20)
Estimated Study Completion Date: April 7, 2027 Identifier: NCT03767244

PSA Relapse

Vaccitech: A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Phase: 1/2
Study Product: VTP-850 (viral vector) prime-boost regimens with booster IM for BCR 
Estimated Study Completion Date: April 2027 Identifier: NCT05617040



CAPItello-281A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with DeNovo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281)

Phase: 3
Study Product: Capivasertib plus abiraterone vs. placebo plus abiraterone
Estimated Study Completion Date: November 2025 Identifier: NCT04493853


Post Abi and/or Enza in mCSPC or mCRPC setting

Propella: Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients with Advanced Prostate Cancer

Phase: 1
Study Product: post Abi and/or Enza (4wk washout)- must have ADT ≥1 month and T 2-49 ng/dL- IM Abi depot + Pred
Estimated Study Completion Date: April 30, 2025 Identifier: NCT04729114

Post Abi, Enza, Apa, and/or Daro (prior chemo allowed)

ARV-766: A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients with Metastatic Castration-Resistant Prostate Cancer

Phase: 1/2
Study Product: post 1-3 ARTT for mCSPC/mCRPC (2 lines chemo allowed)- dose expansion oral ARV-766 (AR PROTAC)
Estimated Study Completion Date: June 27, 2025 Identifier: NCT05067140

MacroGenics: A Phase 2/3, Randomized, Open-label, Study of MGC018 Versus Androgen Receptor Axis-targeted Therapy (Abiraterone or Enzalutamide) in Participants with Metastatic Castration-resistant Prostate Cancer

Phase: 2/3
Study Product: post Doce and post 1L ARTT- MGC018 2 mg/kg IV Q4W vs MGC018 2.7 mg/kg IV Q4W vs ARRT (1:1:1) 
Estimated Study Completion Date: December 2026 Identifier: NCT05551117

Post Doce

MK365: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

Phase: 1b/2
Study Product: Cohort E: Pembro + Lenvatinib; Cohort F: t-NE-Pembro + Lenvatinib; Cohort G: Pembro + Vibostolimab; Cohort H: t-NE-Pembro + Vibostolimab
Estimated Study Completion Date: May 30, 2025 Identifier: NCT02861573

Exelixis Stellar-002 escalation: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Phase: 1b
Study Product: life-prolonging therapies do not exist/are not available or are intolerable- cohort A: XL092 + Nivo vs cohort B: XL092 + Nivo + Ipi vs cohort D: XL092 + Nivo/Relatlimab (MD choice based on slots) 
Estimated Study Completion Date: May 2026 Identifier: NCT05176483

Post 1L ARTT in mCSPC or CRPC setting

C2321001: A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Castration Resistant Prostate Cancer (CRPC) 

Phase: 1
Study Product: PF-06821497
Estimated Study Completion Date: May 6, 2024 Identifier: NCT03460977

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember to talk to your healthcare providers first before making decisions about your plan of care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. To learn more about our trials, call Jennifer at (843) 449-1010 ext. 316 or email us by filling out the form below.